Abstract 2182
Background
Immune checkpoint inhibitors mediated by PD-1 and PD-L1 are promising treatments for various tumors. The PD-L1 expression in tumor cells was found to be correlated with the likelihood of a response to PD-1- or PD-L1-targeted therapy in non-small cell lung cancer (NSCLC). For PD-L1 immunohistochemistry (IHC), 22C3 pharmDx is the only companion diagnostic assay that can identify NSCLC patients suitable for pembrolizumab treatment. Specimens are scored and divided into 3 categories (<1%, 1-49%, ≥50%) based on the tumor proportion score (TPS). The PD-L1 prevalence in NSCLC patients screened for the KEYNOTE-024 trial was 31% with TPS <1%, 39% with TPS 1-49%, and 30% with TPS ≥50%. While specimens used for the IHC 22C3 assay are recommended to be formalin-fixed for 12-72 h, the specimens were fixed in 10% neutral-buffered formalin for less than 6 h in our institution. Thus, we retrospectively assessed the PD-L1 prevalence in NSCLC patients to determine whether the PD-L1 TPS differs according to the duration of formalin fixation.
Methods
We screened consecutive NSCLC patients who underwent tumor biopsy by bronchoscopy between January 2017 and June 2018 at National Hospital Organization Fukuokahigashi Medical Center. In the present study, we only included 70 patients whose tumors were formalin-fixed for less than 6 h and whose PD-L1 expression had been evaluated by IHC with antibodies to human PD-L1 (22C3 pharmDx).
Results
The PD-L1 prevalence in patients with NSCLC in our hospital was 26 (37%) with TPS<1%, 23 (33%) with TPS 1-49%, and 21 (30%) with TPS ≥50%, suggesting that small biopsy samples obtained by bronchoscopy that were formalin-fixed for <6 h are suitable for PD-L1 IHC. We also performed analyzed in 35 surgically-resected NSCLC specimens that had been formalin-fixed for 1-7 days by PD-L1 IHC. The PD-L1 prevalence was 20 (57%) for TPS < 1%, 9 (26%) for TPS 1-49%, and 6 (17%) for TPS ≥50%.
Conclusions
The PD-L1 prevalence in specimens with short-duration formalin fixation was consistent with the results of the KEYNOTE-024 trial. We will present our conclusion regarding these results, including the characteristics of patients and the PD-L1 prevalence in specimens fixed for 12-72 h in our institution, from July 2018 onward.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
National Hospital Organization Fukuokahigashi Medical Center.
Funding
JSPS KAKENHI JP18K15927.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3336 - Survival outcome of non-small cell lung cancer (NSCLC) patients: Comparing results between the database of the Comprehensive Cancer Center Zürich (CCCZ) and the Epidemiological Cancer Registry Zurich and Zug (KKR)
Presenter: Rolf A. Stahel
Session: Poster Display session 1
Resources:
Abstract
2204 - NORA trial (GECP 15/02): Updated results of the Spanish Lung Cancer Group (SLCG) phase II trial of concurrent chemo-radiotherapy (CT-RT) with cisplatin (P) plus metronomic oral vinorelbine (mOV) for unresectable locally advanced non-small cell lung cancer (LA-NSCLC)
Presenter: María Guirado
Session: Poster Display session 1
Resources:
Abstract
1446 - A nomogram to predict outcomes of lung cancer patients after pneumonectomy based on 47 indicators set by principle component analysis
Presenter: Bo Cheng
Session: Poster Display session 1
Resources:
Abstract
1788 - Prognostic and predictive value of 18F-PET/CT on the response to treatment in locally advanced non-small cell lung cancer (NSCLC)
Presenter: Cristina Alfaro Autor
Session: Poster Display session 1
Resources:
Abstract
2299 - Comparison of three different chemotherapy regimens for concomitant chemoradiotherapy in locally advanced non small cell lung cancer
Presenter: Abdurrahman Işıkdoğan
Session: Poster Display session 1
Resources:
Abstract
4211 - Predicting the first failure pattern in patients with inoperable local advanced non-small cell lung cancer (LA-NSCLC) receiving definitive chemoradiotherapy: Establishment and internal validation of a nomogram based on the clinicopathological factors
Presenter: Xueru Zhu
Session: Poster Display session 1
Resources:
Abstract
1550 - Prognostic impact of neutrophil-to-lymphocyte ratio (NLR) pre and post chemoradiotherapy (CRT) in stage III non-small cell lung cancer (NSCLC)
Presenter: Vicente Palomar Abril
Session: Poster Display session 1
Resources:
Abstract
2345 - Meta-analysis evaluating neutropenia incidence with EGFR inhibitors and chemotherapy in patients with NSCLC
Presenter: Bernardo Rapoport
Session: Poster Display session 1
Resources:
Abstract
3747 - Effector CD4+ T-cell induction by thoracic radiotherapy for patients with NSCLC
Presenter: Yu Miura
Session: Poster Display session 1
Resources:
Abstract
3317 - Circulating tumor DNA (ctDNA) analysis in patients (pts) with non-small cell lung cancer (NSCLC) treated with telisotuzumab vedotin (teliso-v), an antibody-drug conjugate targeting c-Met
Presenter: Rebecca Heist
Session: Poster Display session 1
Resources:
Abstract